Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls

Table 1 Baseline characteristics of the study population consisting of patients with familial adenomatous polyposis (FAP) and non-FAP patient controls

	Overall non-FAP group	Overall FAP group	p-value	FAP group A: Celecoxib & UDCA	FAP group B: Celecoxib & placebo	p-value
Number of patients	16	37		19	18
Age at study entry, median/range (yr)	53/23-67	42/22-67	0.092*	42/22-67	41/27-64	0.964*
Sex (n,%)			0.241†			0.618†
Male	5 (31)	18 (49)		10 (53)	8 (44)
Female	11 (69)	19 (51)		9 (47)	10 (56)
Body Mass Index, median/range (kg/m²)	26.1/19.4-44.2	25.6/18.8-34.5	0.779*	26.0/19.2-34.5	25.6/18.8-33.1	0.408*
Spigelman score at last surveillance before entry						0.985†
II		19 (51)‡		10 (53)	9 (50)‡
III		17 (46)‡		9 (47)	8 (44)‡

*The p-value was calculated by the Mann–Whitney U test.
†The p-value was calculated by the Chi-square test.
‡In 1 case data on Spigelman score at last surveillance gastroduodenoscopy before study entry was missing.
Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid.

ISSN: 1750-1172